Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Our RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Our diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, we are leading the charge toward a world in which human potential is no longer hindered by the burden of disease.

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue			152K -	1.49M 876.97%	3.70M 149.43%	14.41M 289.15%	15.98M 10.89%	20.08M 25.61%	40.96M 104.03%	3.65M 91.09%	113.31M 3,005.10%
cost of revenue				393K -	79.31M 20,080.41%		175.43M -	124.17M 29.22%	121.88M 1.84%	10.11M 91.70%	9.21M 8.98%
gross profit			152K -	1.09M 618.42%	-75.61M 7,023.53%	14.41M 119.06%	-159.45M 1,206.20%	-104.09M 34.72%	-80.91M 22.27%	-6.46M 92.01%	104.10M 1,710.19%
selling and marketing expenses											-9.21M -
general and administrative expenses	1.65M -	3.00M 81.32%	10.39M 246.55%	15.99M 53.89%	26.98M 68.66%	39.51M 46.47%	48.87M 23.69%	42.51M 13.01%	46.10M 8.46%	50.51M 9.56%	51.29M 1.54%
selling general and administrative expenses	1.65M -	3.00M 81.32%	10.39M 246.55%	15.99M 53.89%	26.98M 68.66%	39.51M 46.47%	48.87M 23.69%	42.51M 13.01%	46.10M 8.46%	50.51M 9.56%	42.09M 16.68%
research and development expenses	1.92M -	2.40M 24.74%	9.06M 278.16%	40.82M 350.68%	79.31M 94.30%	134.43M 69.50%	175.43M 30.50%	130.94M 25.36%	121.88M 6.93%	115.86M 4.94%	130.01M 12.22%
other expenses	37K -	261K 605.41%	56K 78.54%	-50K 189.29%	-331K 562%	9.55M 2,984.89%	9.74M 1.98%	2.06M 78.87%	4.54M 120.46%	7K 99.85%	1.88M 26,728.57%
cost and expenses	3.57M -	5.39M 50.92%	19.45M 260.59%	56.81M 192.09%	106.28M 87.08%	173.94M 63.65%	224.30M 28.95%	173.45M 22.67%	167.98M 3.16%	166.37M 0.96%	181.30M 8.98%
operating expenses	3.57M -	5.39M 50.92%	19.45M 260.59%	56.81M 192.09%	106.28M 87.08%	173.94M 63.65%	224.30M 28.95%	173.45M 22.67%	167.98M 3.16%	166.37M 0.96%	172.09M 3.44%
interest expense		12K -	86K 616.67%	337K 291.86%	6K 98.22%	22K 266.67%		-16K -		-1.58M -
ebitda	-3.30M -	-4.85M 47.12%	-18.70M 285.49%	-55.58M 197.17%	-102.00M 83.52%	-157.31M 54.22%	-213.23M 35.55%	-153.96M 27.80%	-127.05M 17.48%	-162.72M 28.08%	-58.79M 63.87%
operating income	-3.57M -	-5.39M 50.92%	-19.30M 257.77%	-55.33M 186.70%	-102.58M 85.41%	-159.52M 55.51%	-208.32M 30.59%	-153.38M 26.37%	-127.02M 17.19%	-162.72M 28.11%	-68.00M 58.21%
depreciation and amortization	276K -	281K 1.81%	594K 111.39%	784K 31.99%	2.15M 174.87%	5.58M 158.98%	-4.91M 188.01%	-584K 88.11%	-30K 94.86%	10.11M 33,813.33%	9.21M 8.98%
total other income expenses net	37K -	261K 605.41%	56K 78.54%	205K 266.07%	1.25M 508.29%	12.92M 935.85%	14.68M 13.64%	2.63M 82.11%	4.57M 73.91%	1.58M 65.45%	9.81M 521.42%
income before tax	-3.65M -	-5.14M 41.04%	-19.16M 272.32%	-54.78M 185.99%	-101.33M 84.95%	-146.58M 44.66%	-193.64M 32.10%	-150.75M 22.15%	-122.45M 18.77%	-161.14M 31.60%	-58.19M 63.89%
income tax expense	-330K -	84K 125.45%	44K 47.62%	616K 1,300%	708K 14.94%	69K 90.25%	-14.14M 20,595.65%	-841K 94.05%	-204K 75.74%	681K 433.82%	-677K 199.41%
net income	-3.32M -	-5.23M 57.59%	-19.20M 267.18%	-55.40M 188.55%	-102.03M 84.18%	-146.65M 43.73%	-179.50M 22.40%	-149.91M 16.48%	-122.25M 18.45%	-161.82M 32.38%	-57.51M 64.46%
weighted average shs out	20.93M -	20.93M 0%	10.50M 49.83%	22.80M 117.12%	26.51M 16.28%	28.97M 9.27%	33.87M 16.90%	39.23M 15.83%	51.83M 32.11%	78.86M 52.16%	106.10M 34.55%
weighted average shs out dil	20.93M -	20.93M 0%	10.50M 49.83%	22.80M 117.12%	26.51M 16.28%	28.97M 9.27%	33.87M 16.90%	39.23M 15.83%	51.83M 32.11%	78.86M 52.16%	106.10M 34.55%
eps	-0.16 -	-0.25 56.25%	-1.83 632%	-2.43 32.79%	-3.85 58.44%	-5.06 31.43%	-5.30 4.74%	-3.82 27.92%	-2.36 38.22%	-2.05 13.14%	-0.54 73.66%
epsdiluted	-0.16 -	-0.25 56.25%	-1.83 632%	-2.43 32.79%	-3.85 58.44%	-5.06 31.43%	-5.30 4.74%	-3.82 27.92%	-2.36 38.22%	-2.05 13.14%	-0.54 73.66%

COM:WAVELIFESCIENCES

Wave Life Sciences

Last Close

14.83

08/11 21:00

Market Cap

682.19M

Beta: -

Volume Today

2.39M

Avg: -

Preview